Slide 1

Inhibitor of PI3K- alpha and beta isoforms.

Phase II study:

–

142 pts, relapsed or refractory to ≥ 2 lines of therapy.

–

IV on days 1,8, and 15.

–

Primary endpoint: ORR

–

Results:

•

ORR 61%, CR 15% (n=104 fl pts)

•

Median PFS: 11.2 months

PI3Ki: Copanalisib (BAY 80-6946)

Slide 61